breast cancer

[Signal Transduction and Targeted Therapy] Researchers demonstrated that intracellular cytokine-like protein 1 (CYTL1) played a key role in preventing the robust glycolytic switching characteristics of breast cancer.

[Oncogene] Scientists highlighted the role of the miR-135/zinc finger protein 217 (ZNF217)/methyltransferase-like 13/NANOG axis in the progression of breast cancer (BC), emphasizing potential therapeutic targets ZNF217 silencing and miR-135 upregulation in preventing or treating BC.

[Proceedings of the National Academy of Sciences of the United States of America] Treatment of breast cancer cells with a small-molecule inhibitor of BRD4, JQ1, resulted in no immediate activation of the drug-resistant genes, but long-time treatment or destabilization of LSD1 by PELI1 decommissioned the BRD4/LSD1/NuRD complex.

[Nature Communications] Integrated copy number and transcriptome analysis of 302 TNBC patients revealed that gene alpha-endosulfine (ENSA) exhibited recurrent amplification at the 1q21.3 region and was highly expressed in TNBC.

[Cell Death & Disease] ADRB3 promoted metastasis by inducing mobilization and inhibiting differentiation of both breast cancer cells and myeloid-derived suppressor cells.

[Scientific Reports] Investigators demonstrated that Neuropeptide Y Receptor Y1 (NPY1R) mediated the inhibitory action of NPY on estradiol-stimulated growth of ER+ breast cancer (BC) cells, and its expression served as a biomarker to predict endocrine sensitivity and survival in ER+ BC patients.